The importance of NKG2D in tumor control is highlighted by the fact that tumors release NKG2D ligands MICA/B and ULBP1/2/3 by proteolytic cleavage to escape NKG2D-mediated NK cell cytotoxicity (70) and that antibody targeting the site of proteolytic cleavage prevent release of MICA/B and reduce melanoma metastasis in a humanized mouse model (71). This evidence concerns the gene ULBP1 and neoplasm.